Forbius logo

Forbius

Forbius (Formation Biologics) is a clinical stage company that designs and develops biotherapeutics for treatment of cancer and fibrotic diseases. Formation Biologics (formerly AvidBiologics) is a spin-out from YM BioSciences, developing antibody-drug conjugates (ADCs) for the treatment of cancer.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://forbius.com
Founded2011
Disease Focus
Development StageClinical
STOCK CODENon Listed
Address
101 W 6TH Street, Suite 501, TX 78701
Austin
United States
Email
Contact Number

Formation Biologics (formerly AvidBiologics) is a spin-out from YM BioSciences, developing antibody-drug conjugates (ADCs) for the treatment of cancer.

Formation Biologics is based in MaRS Incubator and holds rights to novel compounds previously engineered by YM Biosciences in collaboration with National Research Council of Canada and Fox Chase Cancer Centre (Philadelphia, USA).

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/forbius” connections=”true” suffix=””]

In Feb 2019, Forbius entered into an collaboration agreement with the Icahn School of Medicine at Mount Sinai and the Myeloproliferative Neoplasm Research Consortium (MPN-RC) to Evaluate AVID200, in Myelofibrosis.

May 2017, Formation Biologics closed Series B financing led by HBM Healthcare Investments. Earlier, In Sep 2014, Formation raised undisclosed funds through private financing, led by Lumira Capital, Merck Lumira Biosciences Fund, MaRS Investment Accelerator Fund, MaRS Innovation, Rosseau Asset Management and companys founding investors. In 2015, Formation recieved US$12.75 Mn grant from the Cancer Prevention and Research Institute of Texas.